Progyny, Inc. (NASDAQ:PGNY) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its position in Progyny, Inc. (NASDAQ:PGNY) by 15.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 425,682 shares of the company’s stock after purchasing an additional 57,606 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.50% of Progyny worth $7,343,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in PGNY. Signaturefd LLC lifted its stake in Progyny by 1,355.0% in the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after buying an additional 1,355 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after acquiring an additional 1,246 shares during the period. Nisa Investment Advisors LLC raised its position in Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after purchasing an additional 1,526 shares during the last quarter. Caitlin John LLC boosted its stake in Progyny by 2,974.8% during the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock worth $57,000 after purchasing an additional 3,183 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in Progyny in the 4th quarter valued at about $74,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Stock Down 1.9 %

Shares of PGNY opened at $21.40 on Thursday. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of 36.90, a price-to-earnings-growth ratio of 2.39 and a beta of 1.33. The company’s fifty day moving average is $21.98 and its 200-day moving average is $18.77. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $33.84.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on PGNY shares. Bank of America increased their target price on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Canaccord Genuity Group increased their target price on Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a report on Friday, February 28th. JPMorgan Chase & Co. boosted their price target on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Finally, BTIG Research upgraded shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price objective on the stock in a report on Monday, March 31st. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Progyny has an average rating of “Hold” and an average price target of $23.64.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.